arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Kiniksa Pharmaceuticals International, plc

KNSA
$88.40 ▼ -7.68 (-7.99%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
39 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
72
Health
Good
Neutral
auto_awesome

Analytical Summary

Kiniksa Pharmaceuticals International, plc shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $6.9B
Dividend Yield —
Revenue Growth 58.1% ↗
Op. Margin 19.0% ↗
ROIC 6.1% ↗
FCF / Share $0.61 →
Trailing P/E 144.9x
Price / Book 9.7x
FCF Yield 0.7%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$285.97M
↑ +58.1% —
Net Income Profit after all expenses
$22.59M
↑ +164.6% —
Operating Margin Operating profit as % of sales
19.0%
↑ +69.9% 60th
FCF / Share Free cash flow per share
$0.61
↑ +37.1% —

Health Breakdown

Profitability
68
Returns
69
Cash Quality ↑
88

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 10 years · 39 quarters